CHANTIX Drug Patent Profile

Which patents cover Chantix, and when can generic versions of Chantix launch?

Chantix is a drug marketed by Pf Prism Cv and is included in one NDA.

The generic ingredient in CHANTIX is varenicline tartrate. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Chantix

A generic version of CHANTIX was approved as varenicline tartrate by PAR PHARM INC on August 11^th, 2021.

Summary for CHANTIX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	166
Patent Applications:	155
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for CHANTIX
Drug Sales Revenues:	Drug sales revenues for CHANTIX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CHANTIX
What excipients (inactive ingredients) are in CHANTIX?	CHANTIX excipients list
DailyMed Link:	CHANTIX at DailyMed

See drug prices for CHANTIX

See drug sales revenues for CHANTIX

Recent Clinical Trials for CHANTIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 3
Mayo Clinic	Early Phase 1
Duke University	Phase 4

See all CHANTIX clinical trials

Pharmacology for CHANTIX

Drug Class	Cholinergic Receptor Agonist Partial Cholinergic Nicotinic Agonist
Mechanism of Action	Cholinergic Agonists Partial Cholinergic Nicotinic Agonists

Anatomical Therapeutic Chemical (ATC) Classes for CHANTIX

N07BA	Drugs used in nicotine dependence
N07B	DRUGS USED IN ADDICTIVE DISORDERS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

S01XA	Other ophthalmologicals
S01X	OTHER OPHTHALMOLOGICALS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for CHANTIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CHANTIX	Tablets	varenicline tartrate	0.5 mg and 1 mg	021928	5	2010-05-10

US Patents and Regulatory Information for CHANTIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	CHANTIX	varenicline tartrate	TABLET;ORAL	021928-001	May 10, 2006		DISCN	Yes	No
Pf Prism Cv	CHANTIX	varenicline tartrate	TABLET;ORAL	021928-002	May 10, 2006		DISCN	Yes	No

International Patents for CHANTIX

See the table below for patents covering CHANTIX around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	033635	SALES TARTRATO DE 5,8,14-TRIAZATETRACICLO (10.3.1.0 2,11.0 4,9)-EXADECA--2(11),3,5,7,9-PENTAENO Y COMPOSICIONES FARMACEUTICAS DE LAS MISMAS.
European Patent Office	1259489	COMPOSES AZAPOLYCYCLIQUES A FUSION ARYLE (ARYL FUSED AZAPOLYCYCLIC COMPOUNDS)
Portugal	1259489
Denmark	1044189
Slovakia	287170
African Regional IP Organization (ARIPO)	1473	Tartrate salts of 5,8,14-triazatetracyclo{10.3.1.0 .0] hexadeca2(11),3,5,7.9-pentaene and pharmaceutical compositions thereof.

Supplementary Protection Certificates for CHANTIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1044189	91442	Luxembourg		91442, EXPIRES: 20210926
1044189	300355	Netherlands		300355, 20181113, EXPIRES: 20220425
1044189	325	Finland
1044189	SPC021/2008	Ireland		SPC021/2008: 20081105, EXPIRES: 20210925
1044189	08C0039	France		PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926
1044189	C01044189/01	Switzerland		PRODUCT NAME: VARENICLIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57736 21.12.2006